- Home
- PLX
as of 12-03-2025 2:54pm EST
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | HACKENSACK |
| Market Cap: | 204.9M | IPO Year: | 1998 |
| Target Price: | $12.00 | AVG Volume (30 days): | 570.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.32 - $3.10 | Next Earning Date: | 11-13-2025 |
| Revenue: | $61,840,000 | Revenue Growth: | 35.41% |
| Revenue Growth (this year): | 14.53% | Revenue Growth (next year): | 75.77% |
AI-Powered PLX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Protalix BioTherapeutics Inc. (DE) (PLX)
Director
Avg Cost/Share
$1.87
Shares
168
Total Value
$314.16
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bar-Shalev Amos | PLX | Director | Nov 18, 2025 | Sell | $1.87 | 168 | $314.16 | 0 |
Compare PLX vs Leading Stocks
See how PLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PLX Protalix BioTherapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.